Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol DOI Creative Commons
Saule Balmagambetova, Zhenisgul Tlegenova, Bekbolat Zholdin

et al.

Diagnostics, Journal Year: 2022, Volume and Issue: 12(11), P. 2714 - 2714

Published: Nov. 6, 2022

The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity chemotherapy. This research aims to create a feasible algorithm for early diagnosis antitumor therapy in breast patients. paper represents protocol prospective cohort study with N 120 eligible participants admitted anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients examined five times every three months six biomarkers,: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously echocardiographic methods, including speckle tracking. adjusted relative (aOR) interrupting an entire course chemotherapy due events assessed using multiple analyses proportional Cox risks. model also assess associations between baseline biomarker values time events. Moreover, partly conditional survival models applied determine repeated assessments changes biomarkers from therapy-related dysfunction. All regimen, LVEF, at risk, values, age. decision-tree principal component analysis (PCA) methods applied. Thus, patterns detected.

Language: Английский

Prevalence, incidence, and mortality rates of breast cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014–2019 DOI Creative Commons
Anna Midlenko, Kamilla Mussina, Gulnur Zhakhina

et al.

Frontiers in Public Health, Journal Year: 2023, Volume and Issue: 11

Published: April 17, 2023

Background Although there are numerous sources of epidemiologic information on breast cancer in Kazakhstan, none them have specifically examined the burden this disease. Therefore, article aims to provide an overview prevalence, incidence, mortality, and distribution changes over time Kazakhstan based nationwide large-scale healthcare data from National Registry order encourage more research impact various diseases at regional national levels. Methods The study cohort included all adult women older than 25 years who were diagnosed with any clinical setting Republic during period 2014–2019. extracted Unified Nationwide Electronic Health System (UNEHS) get descriptive statistics, mortality rate calculations Cox proportional hazards regression model. All survival functions factors associated tested for significance. Results population ( n = 55,465) comprised subjects age diagnosis 97 years, a mean 55.7 ± 12.0 years. majority belonged group 45–59 which is 44.8% cohort. all-cause 16%. prevalence increased 30.4 per 10,000 2014 50.6 2019. incidence varied 4.5 2015 7.3 2016. Mortality rates stable high senile patients (75–89 old). Breast was positively had been diabetes, HR 1.2 (95% CI, 1.1–2.3), whereas it negatively arterial hypertension, 0.4 0.4–0.5). Conclusion Overall, experiencing increase cases, but has started decline. switch mammography screening could reduce rate. These findings should be utilized help determine what control priorities utilized, including need implement efficient affordable prevention programs.

Language: Английский

Citations

11

Early Diagnosis of Chemotherapy-Linked Cardiotoxicity in Breast Cancer Patients Using Conventional Biomarker Panel: A Prospective Study Protocol DOI Creative Commons
Saule Balmagambetova, Zhenisgul Tlegenova, Bekbolat Zholdin

et al.

Diagnostics, Journal Year: 2022, Volume and Issue: 12(11), P. 2714 - 2714

Published: Nov. 6, 2022

The prognosis of cancer treatment depends on, among other aspects, the cardiotoxicity chemotherapy. This research aims to create a feasible algorithm for early diagnosis antitumor therapy in breast patients. paper represents protocol prospective cohort study with N 120 eligible participants admitted anthracyclines and/or trastuzumab. These patients will be allocated into four risk groups regarding potential cardiotoxic complications. Patients examined five times every three months six biomarkers,: cardiac troponin I (cTnI), brain natriuretic peptide (BNP), C-reactive protein (CRP), myeloperoxidase (MPO), galectin-3 (Gal-3), and D-dimer, simultaneously echocardiographic methods, including speckle tracking. adjusted relative (aOR) interrupting an entire course chemotherapy due events assessed using multiple analyses proportional Cox risks. model also assess associations between baseline biomarker values time events. Moreover, partly conditional survival models applied determine repeated assessments changes biomarkers from therapy-related dysfunction. All regimen, LVEF, at risk, values, age. decision-tree principal component analysis (PCA) methods applied. Thus, patterns detected.

Language: Английский

Citations

9